Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock. The timing, manner, price, and amount of any repurchases will be determined at the Company's discretion based on a variety of factors,...
The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications for Sarclisa intravenous (IV) formulation, Sanofi SA (SNY) said in a statement on Monday. Sarclisa...
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), has released new data from the first real-world, decentralized study evaluating the quality of life impacts of Huntington's disease (HD) chorea. The study assessed patient- and caregiver-reported outcomes and examined...
BioCardia, Inc. (BCDA) shares soared 48.13 percent, gaining $0.4423 to $1.3613 on Friday after the company announced that it received meeting minutes from the U.S. Food and Drug Administration confirming that its ongoing CardiAMP Heart Failure II Trial may support a Premarket Approval.
Monday, Standard BioTools Inc. (LAB) announced an agreement with Treeline Biosciences, Inc., a clinical-stage biopharma company, to combine in an all-stock transaction. The transaction values Standard BioTools at net cash delivered at closing, plus $10 million, which is estimated to be $460 million....
Johnson & Johnson (JNJ) on Monday announced a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company for $1 billion in cash. The transaction is expected to close later this year. The acquisition is expected to expand Johnson & Johnson's oncology pipeline with Firefly Bio's...
Monday, Tango Therapeutics, Inc. (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib. During the study, patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal...
Fractyl Health, Inc. (GUTS), a clinical-stage metabolic therapeutics company, on Thursday announced positive one-year results for Revita from its REVEAL-1 Cohort study. Revita is the company's lead product candidate, designed to remodel the duodenal lining of the small intestine through a one-time,...
argenx SE (ARGX), an immunology company, on Wednesday reported positive data for efgartigimod in autoimmune rheumatic diseases, including myositis and Sjogren's disease, ahead of presentations at the EULAR 2026 Congress in London. In the ongoing ALKIVIA+ extension study in myositis, patients who continued...
Gilead Sciences, Inc. (GILD) announced Tuesday positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP). ALP is a key liver marker...
Pfizer, Inc. (PFE) announced Monday that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without...
June's FDA calendar offers plenty for investors to keep a close eye on. Among the key names are Spero Therapeutics, awaiting an FDA decision on its antibiotic for complicated urinary tract infections; Kiniksa Pharma, seeking approval for a technology transfer of the manufacturing process for Arcalyst drug substance; and Merck, pursuing the first FDA approval for its WELIREG - KEYTRUDA combination.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Retailer Target Corp. is recalling select Up & Up Baby Wipes, due to potential microbial contamination, according to the U.S. Food and Drug Administration. The recall involves Up & Up FragranceFree Baby Wipes and Up & Up Fresh Cucumber Scented Baby Wipes with various counts and UPC numbers. The impacted wipes were manufactured by a supplier, Sapro Temizlik Urunleri, and sold at Target stores...
a2 Milk Company Ltd. (ACOPF, A2M.AX), a dairy company, announced a recall of select infant milk formula, manufactured by Synlait Milk Limited and sold only in the United States, citing the presence of cereulide. The recall involves three batches of a2 Platinum USA label infant milk formula, comprising...
Alvotech (ALVO), a biotechnology company, announced that its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for intravenous administration, has been accepted for review by the FDA. According to the company, the Biologics License Application...
Chinese researchers have carried out the world's first transplant of two pig kidneys and a pig liver into a 53-year-old brain-dead man at the same time, marking an important step forward in xenotransplantation. The surgery was conducted at the Second Affiliated Hospital of Guangxi Medical University...
The Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) have launched a joint plan to help African countries prepare for and respond to the ongoing Ebola outbreak caused by the Bundibugyo virus. The joint initiative comes as authorities in the Democratic...
A new study suggests that doing a moderate amount of strength training every week may help people live longer, especially when it is combined with regular aerobic exercise such as walking, running, cycling, or swimming. Researchers analyzed data from three large long-term health studies involving...
Enanta Pharmaceuticals Inc. (ENTA), a clinical-stage biotechnology company focusing on viral infections and immunological diseases, will be highlighting its investigational programs - Zelicapavir and EPS-3903 - at the American Thoracic Society (ATS) International Conference today.